JP2588109B2 - 鎮痛剤 - Google Patents
鎮痛剤Info
- Publication number
- JP2588109B2 JP2588109B2 JP5085322A JP8532293A JP2588109B2 JP 2588109 B2 JP2588109 B2 JP 2588109B2 JP 5085322 A JP5085322 A JP 5085322A JP 8532293 A JP8532293 A JP 8532293A JP 2588109 B2 JP2588109 B2 JP 2588109B2
- Authority
- JP
- Japan
- Prior art keywords
- silicate
- present
- substance
- analgesic
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 25
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims abstract 9
- 230000000202 analgesic effect Effects 0.000 claims description 15
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical group [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 7
- 235000019353 potassium silicate Nutrition 0.000 claims description 7
- -1 alkali metal salt Chemical class 0.000 claims description 5
- 239000004115 Sodium Silicate Substances 0.000 claims description 4
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 30
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 16
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 13
- 229910052710 silicon Inorganic materials 0.000 description 13
- 239000010703 silicon Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229960001340 histamine Drugs 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008827 biological function Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 235000019795 sodium metasilicate Nutrition 0.000 description 3
- POWFTOSLLWLEBN-UHFFFAOYSA-N tetrasodium;silicate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-][Si]([O-])([O-])[O-] POWFTOSLLWLEBN-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000033041 Somatoform disorder gastrointestinal Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RLQWHDODQVOVKU-UHFFFAOYSA-N tetrapotassium;silicate Chemical compound [K+].[K+].[K+].[K+].[O-][Si]([O-])([O-])[O-] RLQWHDODQVOVKU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
- Silicon Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Silicon Polymers (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5085322A JP2588109B2 (ja) | 1993-03-19 | 1993-03-19 | 鎮痛剤 |
| US08/213,065 US5534509A (en) | 1993-03-19 | 1994-03-15 | Pharmaceutical composition regulating function of a living body |
| TW083102311A TW270085B (cg-RX-API-DMAC7.html) | 1993-03-19 | 1994-03-17 | |
| KR1019940005468A KR100268575B1 (ko) | 1993-03-19 | 1994-03-18 | 규산폴리머,그것을 함유하는 약제 및 그 제조방법 |
| CN94102949A CN1078469C (zh) | 1993-03-19 | 1994-03-18 | 生物机能调节物质 |
| SG1996001796A SG45236A1 (en) | 1993-03-19 | 1994-03-18 | A pharmaceutical composition regulating function of a living body |
| ES94104300T ES2127302T3 (es) | 1993-03-19 | 1994-03-18 | Composiciones farmaceuticas que incluyen polimeros en silicato. |
| EP94104300A EP0621038B1 (en) | 1993-03-19 | 1994-03-18 | Pharmaceutical compositions containing silicate polymers |
| DK94104300T DK0621038T3 (da) | 1993-03-19 | 1994-03-18 | Farmaceutiske præparater indeholdende silikatpolymere |
| DE69414904T DE69414904T2 (de) | 1993-03-19 | 1994-03-18 | Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen |
| AT94104300T ATE173932T1 (de) | 1993-03-19 | 1994-03-18 | Silikat-polymer enthaltende pharmazeutische zusammensetzungen |
| US08/590,509 US5658896A (en) | 1993-03-19 | 1996-01-24 | Pharmaceutical composition regulating function of a living body |
| US08/841,574 US5807951A (en) | 1993-03-19 | 1997-04-30 | Pharmaceutical composition regulating function of a living body |
| KR1020000021689A KR100294580B1 (ko) | 1993-03-19 | 2000-04-24 | 규산 폴리머를 함유하는 이상지각개선제 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5085322A JP2588109B2 (ja) | 1993-03-19 | 1993-03-19 | 鎮痛剤 |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18421496A Division JP2727442B2 (ja) | 1996-06-24 | 1996-06-24 | 異常知覚改善剤 |
| JP18421396A Division JP2727441B2 (ja) | 1996-06-24 | 1996-06-24 | 抗アレルギー剤 |
| JP8184215A Division JP2698908B2 (ja) | 1996-06-24 | 1996-06-24 | 生体機能調整物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06271471A JPH06271471A (ja) | 1994-09-27 |
| JP2588109B2 true JP2588109B2 (ja) | 1997-03-05 |
Family
ID=13855390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5085322A Expired - Fee Related JP2588109B2 (ja) | 1993-03-19 | 1993-03-19 | 鎮痛剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5534509A (cg-RX-API-DMAC7.html) |
| EP (1) | EP0621038B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2588109B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR100268575B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1078469C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE173932T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69414904T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK0621038T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2127302T3 (cg-RX-API-DMAC7.html) |
| SG (1) | SG45236A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW270085B (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4033936B2 (ja) * | 1997-01-08 | 2008-01-16 | 日本臓器製薬株式会社 | 一酸化窒素産生抑制剤 |
| JPH1180005A (ja) * | 1997-09-12 | 1999-03-23 | Nippon Zoki Pharmaceut Co Ltd | 骨粗鬆症治療剤 |
| KR19990044835A (ko) * | 1997-11-28 | 1999-06-25 | 고니시 진우에몬 | 생약추출물 |
| CN1272365A (zh) | 1999-04-15 | 2000-11-08 | 日本脏器制药株式会社 | 新型生理活性物质 |
| CN1312080A (zh) * | 2000-02-18 | 2001-09-12 | 日本脏器制药株式会社 | 含有脂肪酸的组合物 |
| KR100532915B1 (ko) * | 2002-10-29 | 2005-12-02 | 삼성전자주식회사 | 단당류계 또는 올리고당류계 포로젠을 포함하는 다공성층간 절연막을 형성하기 위한 조성물 |
| JP4145262B2 (ja) * | 2004-03-23 | 2008-09-03 | 三洋電機株式会社 | 積層セラミック基板 |
| KR101307999B1 (ko) | 2004-12-01 | 2013-09-12 | 니폰 조키 세야쿠 가부시키가이샤 | 건조물 및 그 제조방법 |
| US20060134646A1 (en) * | 2004-12-17 | 2006-06-22 | Ansari Aftab A | Method for treatment of HIV infection |
| US20100278935A1 (en) * | 2007-07-30 | 2010-11-04 | Stacey William C | Immune System Modulator Formulation |
| EP3939599A3 (en) | 2007-10-15 | 2022-03-16 | HS Pharmaceuticals, LLC | Silicate containing compositions and methods of treatment |
| GB0805279D0 (en) * | 2008-03-20 | 2008-04-30 | Univ Nottingham Trent | Food supplement |
| EP2151466A1 (en) * | 2008-08-01 | 2010-02-10 | SiNatur GmbH | Biologically active silicic acid |
| DE102010008981A1 (de) | 2010-02-24 | 2011-08-25 | Bayer Innovation GmbH, 40225 | Siliciumhaltiges, biologisch degradierbares Material zur pro-angiogenetischen Therapie |
| DE102010008982A1 (de) | 2010-02-24 | 2011-08-25 | Bayer Innovation GmbH, 40225 | Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie |
| TWI483729B (zh) | 2010-03-11 | 2015-05-11 | Nippon Zoki Pharmaceutical Co | 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑 |
| CN103476923B (zh) | 2010-10-14 | 2015-04-29 | 日本脏器制药株式会社 | 软骨细胞中的胶原蛋白和蛋白聚糖合成的促进方法 |
| BR112013025157A2 (pt) * | 2011-03-31 | 2019-09-24 | Galderma Res & Dev | composições compreendendo um produto de carga e pelo menos um material com base em sílica bioabsorvível e biodegradável |
| GB201402672D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Materials and methods relating to stabilised polymeric silicate compositions |
| GB201402669D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Stabilised silicate compositions and their uses |
| CN105943566A (zh) * | 2016-04-21 | 2016-09-21 | 叶卫斌 | 水溶性硅与中药材或食材提取物之复方制剂的制备方法 |
| US11007217B2 (en) | 2016-08-10 | 2021-05-18 | United Kingdom Research And Innovation | Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy |
| CN110818902B (zh) * | 2019-11-05 | 2021-11-16 | 塔里木大学 | 一种酰氧化聚硅酸化合物及其制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB697351A (en) * | 1951-01-16 | 1953-09-23 | Masuichi Takino | Improved process for the manufacture of nerve sedatives |
| US3959566A (en) * | 1974-10-21 | 1976-05-25 | E. I. Du Pont De Nemours And Company | Process for preparing polymeric surfaces to improve antistatic and soil resistant properties |
| US4036787A (en) * | 1975-09-12 | 1977-07-19 | Blount David H | Process for the production of epoxy silicate compounds and polymers |
| US4039474A (en) * | 1975-10-20 | 1977-08-02 | Nalco Chemical Company | Silica-alumina catalysts |
| US4056937A (en) * | 1976-01-08 | 1977-11-08 | Kyokado Engineering Co. Ltd. | Method of consolidating soils |
| US4089883A (en) * | 1976-07-09 | 1978-05-16 | Blount David H | Process for the production of organic hydroxy silicate compounds and their condensation products |
| US4138421A (en) * | 1977-01-06 | 1979-02-06 | Blount David H | Process for the polymerization of allyl halides to produce poly(allylsilicoformate) polymers |
| JPS53101515A (en) * | 1977-02-17 | 1978-09-05 | Nippon Zoki Pharmaceutical Co | Medicine having anodyne * sedative and antiallergic activity and production thereof |
| JPS5777697A (en) * | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| JPS57183720A (en) * | 1981-05-01 | 1982-11-12 | Junji Mitani | Health drug for fish farming |
| JPS5835117A (ja) * | 1981-08-25 | 1983-03-01 | Nippon Zoki Pharmaceut Co Ltd | 新規生理活性物質ｎｓｈ |
| JPS58121217A (ja) * | 1982-01-13 | 1983-07-19 | Takeo Kagitani | 火傷薬 |
| US4640361A (en) * | 1985-12-13 | 1987-02-03 | Halliburton Company | Thermally responsive aqueous silicate mixtures and use thereof |
| JPS62145022A (ja) * | 1985-12-18 | 1987-06-29 | Sofuto Shirika Kk | 食中毒症用薬剤 |
| KR960009766B1 (ko) * | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| JP2651674B2 (ja) * | 1987-07-23 | 1997-09-10 | 日本臓器製薬 株式会社 | 新規生理活性物質及びその製造方法 |
| US4863518A (en) * | 1987-10-19 | 1989-09-05 | Blount David H | Production of polyol-alkali metal silicate glass emulsion |
| US4985254A (en) * | 1987-11-06 | 1991-01-15 | Nippon Zoki Pharmaceutical Co., Ltd. | Method of treating ischemic diseases |
| EP0341209B1 (en) * | 1988-04-30 | 1993-09-15 | Nippon Zoki Pharmaceutical Co. Ltd. | Physiologically active substances, a process for preparation and pharmaceutical compositions thereof |
| SE461156B (sv) * | 1988-05-25 | 1990-01-15 | Eka Nobel Ab | Saett foer framstaellning av papper varvid formning och avvattning aeger rum i naervaro av en aluminiumfoerening, ett katjoniskt retentionsmedel och en polymer kiselsyra |
| JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
| EP0479218B1 (en) * | 1990-10-01 | 1994-03-30 | Suido Kiko Kabushiki Kaisha | Flocculant for water treament and method for producing it |
| JP2594222B2 (ja) * | 1993-09-28 | 1997-03-26 | 日本臓器製薬株式会社 | 新規生理活性物質−ｋｆ |
| US5523295A (en) * | 1994-07-06 | 1996-06-04 | Brandeis University | Method for treating and preventing alzheimer's disease |
-
1993
- 1993-03-19 JP JP5085322A patent/JP2588109B2/ja not_active Expired - Fee Related
-
1994
- 1994-03-15 US US08/213,065 patent/US5534509A/en not_active Expired - Fee Related
- 1994-03-17 TW TW083102311A patent/TW270085B/zh active
- 1994-03-18 KR KR1019940005468A patent/KR100268575B1/ko not_active Expired - Fee Related
- 1994-03-18 ES ES94104300T patent/ES2127302T3/es not_active Expired - Lifetime
- 1994-03-18 DE DE69414904T patent/DE69414904T2/de not_active Expired - Fee Related
- 1994-03-18 EP EP94104300A patent/EP0621038B1/en not_active Expired - Lifetime
- 1994-03-18 DK DK94104300T patent/DK0621038T3/da active
- 1994-03-18 SG SG1996001796A patent/SG45236A1/en unknown
- 1994-03-18 AT AT94104300T patent/ATE173932T1/de not_active IP Right Cessation
- 1994-03-18 CN CN94102949A patent/CN1078469C/zh not_active Expired - Fee Related
-
1996
- 1996-01-24 US US08/590,509 patent/US5658896A/en not_active Expired - Fee Related
-
1997
- 1997-04-30 US US08/841,574 patent/US5807951A/en not_active Expired - Fee Related
-
2000
- 2000-04-24 KR KR1020000021689A patent/KR100294580B1/ko not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| ＣＨＥＭ．ＰＨＡＲＭ．ＢＵＬＬ．，ＶＯＬ．２７，ＮＯ．８（１９７９），Ｐ．１７３３−１７３９ |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100268575B1 (ko) | 2000-11-01 |
| ES2127302T3 (es) | 1999-04-16 |
| KR940021071A (ko) | 1994-10-17 |
| US5534509A (en) | 1996-07-09 |
| DE69414904T2 (de) | 1999-05-12 |
| US5658896A (en) | 1997-08-19 |
| JPH06271471A (ja) | 1994-09-27 |
| CN1078469C (zh) | 2002-01-30 |
| US5807951A (en) | 1998-09-15 |
| TW270085B (cg-RX-API-DMAC7.html) | 1996-02-11 |
| DE69414904D1 (de) | 1999-01-14 |
| KR100294580B1 (ko) | 2001-07-03 |
| EP0621038A1 (en) | 1994-10-26 |
| EP0621038B1 (en) | 1998-12-02 |
| CN1101260A (zh) | 1995-04-12 |
| ATE173932T1 (de) | 1998-12-15 |
| DK0621038T3 (da) | 1999-08-16 |
| SG45236A1 (en) | 1998-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2588109B2 (ja) | 鎮痛剤 | |
| CN102079794B (zh) | 用于医药装置和药物制剂中的含有木葡聚糖的粘膜粘附性制剂 | |
| Kimball et al. | The use of dilatin in the treatment of epilepsy | |
| JPS63270626A (ja) | 抗潰瘍剤 | |
| EP1094809A2 (en) | Use of histamine h2 mimicking substances for the treatment of multiple sclerosis | |
| JP2732109B2 (ja) | 痴呆治療剤 | |
| JP3113619B2 (ja) | 抗炎症剤 | |
| JP2727441B2 (ja) | 抗アレルギー剤 | |
| JP2698908B2 (ja) | 生体機能調整物質 | |
| JP2948784B2 (ja) | 末梢血流改善剤 | |
| JP2727442B2 (ja) | 異常知覚改善剤 | |
| Hartman | Studies on the function and clinical use of cortin | |
| SE467340B (sv) | Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist | |
| EP0448029B1 (en) | Novel pharmaceutical uses of forskolin derivatives | |
| Girard | Ketotifen and bronchial hyperreactivity in asthmatic patients | |
| CN101559046A (zh) | 小分子糖醇组合物对鼻部疾病的治疗作用 | |
| DE3141970A1 (de) | Arzneimittel zur behandlung der durch den virus der herpes-gruppe erzeugten erkrankungen | |
| Szczeklik et al. | Ketotifen versus sodium cromoglycate in the therapy of allergic (extrinsic) bronchial asthma | |
| JPH10338631A (ja) | 抗不安剤 | |
| Gøtzsche et al. | Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers | |
| US5017570A (en) | Dibenzoxazepine compounds useful in the treatment of cerebral vasospasm or its sequela | |
| JPH08510470A (ja) | Ｔリンパ球を含有する感染症治療用医薬組成物 | |
| JPH0959158A (ja) | ベンズイミダゾール誘導体を含有するぜん息治療剤 | |
| JPS59222412A (ja) | 心臓疾患治療薬 | |
| Sakai et al. | Protective effect of an α2-adrenoceptor antagonist, midaglizole, against allergen-provoked late asthmatic responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071205 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081205 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091205 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101205 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111205 Year of fee payment: 15 |
|
| LAPS | Cancellation because of no payment of annual fees |